DUBLIN – Bavarian Nordic A/S lost half its market value Friday when an interim analysis showed that a phase III trial of its cancer vaccine, Prostvac (rilimogene galvacirepvec/rilimogene glafolivec), was not going to deliver a good result. The trial's independent data monitoring committee recommended that the study in patients with metastatic castration-resistant prostate cancer be stopped for futility.